Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Synflorix™ receives European marketing authorisation for additional pneumonia indication
GSK today announced that the European Commission (EC) has granted marketing authorisation for an additional indication for Synflorix™
-
GSK launches global consortium with six renowned cancer research centres
GSK announced today the formation of the Oncology Clinical and Translational Consortium (OCTC)
-
Regulatory Update - GSK receives positive CHMP opinion for Cervarix™ two-dose schedule
CHMP is recommending marketing authorisation for a 2-dose schedule in 9-14yo girls for GSK's cervical cancer vaccine, Cervarix™.
-
H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
GSK announced FDA has approved its pandemic Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted for the immunisation of adults 18+.
-
GSK Responds to FDA Decision on Avandia (rosiglitazone)
GSK announced the FDA has eased restrictions on patient access to Avandia (rosiglitazone), following an committee review in June 2013.
-
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV
ViiV announced that the CHMP of EMA has issued a positive opinion recommending marketing authorisation for Tivicay® (dolutegravir).
-
GSK and Amicus Therapeutics announce revised Fabry agreement
GSK & Amicus announced that Amicus has obtained global rights to develop chaperone migalastat HCl as monotherapy for Fabry disease.
-
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD
GSK & THRX announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®.
-
Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children
A simple low-cost device that helps newborn babies to breathe has been awarded $1million in the first GSK and Save the Children Award
-
GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease
Study did not meet the primary endpoint measure.
-
GSK names inaugural winners in unique competition for academic drug hunters
GSK announced selection of eight winners in its first Discovery Fast Track competition.
-
GSK announces new apprentice and graduate engineering opportunities in the UK during Tomorrow’s Engineers Week
GSK today announced the recruitment of 140 new apprentices over the next two years in the UK - of which a third will be in engineering.
-
GSK announces data to support Cervarix® two-dose schedule for the prevention of cervical cancer in 9-14 year old girls
GSK today announced the results of a Phase III study of its HPV vaccine, Cervarix.
-
New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs
GSK & BMGF announced the launch of initiative that will endeavour to make vaccines more resistant to heat, reducing need for refrigeration.
-
GSK to create a new Centre of Excellence for Sustainable Chemistry in Brazil
GSK announced it's formed new collaboration with FAPESP to create a new Centre of Excellence for Sustainable Chemistry in Brazil.
-
ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV announced submission in EU for STR combining dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) for treatment of people with HIV.
-
Synflorix™ receives positive opinion from the CHMP in Europe for additional pneumonia indication
GSK announced that CHMP has issued a positive opinion for Synflorix™, a paediatric pneumococcal conjugate vaccine.
-
GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma
GSK announced the submission of a New Drug Application in the US for ICS treatment, FF administered using the ELLIPTA™ dry powder inhaler.
-
Results announcement for the third quarter 2013
GSK announces Q3 core EPS growth of 16% and dividend of 19p
-
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV announced submission application in the US for STR combining dolutegravir, abacavir and lamivudine for treatment of people with HIV-1.
